US CPI for January 2026 cooled to 2.4% YoY, slightly below the 2.5% consensus. This disinflationary signal provided a tailwind for APAC markets, though thin volumes due to holidays prevented a major rally.
Team Sahi
Market snapshot: Asia-Pacific equity indices showed marginal gains on Monday, February 16, 2026, as investors processed the latest US Consumer Price Index (CPI) data. The Australian S&P/ASX 200 edged up 0.15%, while Japan's Nikkei 225 rose 0.30%. The positive sentiment was primarily driven by a softer-than-expected US inflation print, which bolstered hopes for a recalibration of Federal Reserve monetary policy. However, trading activity remained muted across the region due to the 'President's Day' holiday in the United States and the ongoing Lunar New Year holidays in several Asian jurisdictions.
Summary: US CPI for January 2026 cooled to 2.4% YoY, slightly below the 2.5% consensus. This disinflationary signal provided a tailwind for APAC markets, though thin volumes due to holidays prevented a major rally.
The 2.4% inflation print is a critical milestone for the current economic cycle. While Core CPI remains slightly stickier at 2.5%, the headline deceleration suggests that the restrictive policy stance of late 2025 is effectively dampening price pressures. For APAC traders, the immediate focus remains on currency fluctuations, particularly the USD/JPY and AUD/USD, which are sensitive to narrowing yield differentials as US Treasury yields soften on the back of this data.
While a 2.4% CPI print is a positive signal for global risk appetite, the true test will be the sustainability of this trend in the face of volatile energy costs and labor market tightness.
High Performance Trading with SAHI.
Synthetically modified: AI-generated content by Sahi Live News Engine.
Related
Recent
Fed's 2026 Outlook: Economic Resilience Meets Persistent Inflationary Pressures
Geopolitical Brinkmanship: Trump-Iran Tensions and the Indian Market Outlook
Zydus Lifesciences Disrupts Respiratory Care with India’s First Drug-Free Device 'Pepair' at ₹990
Infosys Pivots to 'AI-First' Era: New Framework Targets $300 Billion Market Opportunity
Zydus Lifesciences Disrupts Respiratory Care with India’s First Affordable Drug-Free Device ‘PepairTM’ at ₹990